Michael E Wechsler, Parameswaran Nair, Benjamin Terrier, Bastian Walz, Arnaud Bourdin, David R W Jayne, David J Jackson, Florence Roufosse, Lena Börjesson Sjö, Ying Fan, Maria Jison, Christopher McCrae, Sofia Necander, Anat Shavit, Claire Walton, Peter A Merkel
BACKGROUND: Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis characterized by eosinophilic inflammation. Benralizumab, a monoclonal antibody against the interleukin-5α receptor expressed on eosinophils, may be an option for treating EGPA. METHODS: We conducted a multicenter, double-blind, phase 3, randomized, active-controlled noninferiority trial to evaluate the efficacy and safety of benralizumab as compared with mepolizumab. Adults with relapsing or refractory EGPA who were receiving standard care were randomly assigned in a 1:1 ratio to receive benralizumab (30 mg) or mepolizumab (300 mg) subcutaneously every 4 weeks for 52 weeks...
February 23, 2024: New England Journal of Medicine